에스토니아 - 에스토니아어 - Ravimiamet

meda pharma sia - formoterool - inhalatsioonipulber - 6mcg 1annus 60annus 2tk; 6mcg 1annus 60annus 1tk; 6mcg 1annus 100annus 2tk

에스토니아 - 에스토니아어 - Ravimiamet

meda pharma sia - formoterool - inhalatsioonipulber - 12mcg 1annus 60annus 2tk; 12mcg 1annus 100annus 2tk; 12mcg 1annus 60annus 10tk; 12mcg 1annus 100annus 6tk; 12mcg 1annus 60annus 1tk; 12mcg 1annus 100annus 1tk

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatiid - osteoporosis; osteoporosis, postmenopausal - kaltsiumi homöostaas - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - eesnäärmevähk - diagnostilised radiofarmatseutilised ühendid - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).